CAPTRUST Financial Advisors
CYCN icon

CAPTRUST Financial Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,631
Closed -$60.3K – 2650
2023
Q2 		$60.3K Sell
14,631
-1
-0% -$5 ﹤0.01% 2417
2023
Q1 		$127K Buy
+14,632
New +$185K ﹤0.01% 2129

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CAPTRUST Financial Advisors's CYCN Position: Q3 2023 in Review

CAPTRUST Financial Advisors sold out of Cyclerion Therapeutics (CYCN) in Q3 2023, closing a stake of 14,631 shares — an estimated $60.3K sold.

CAPTRUST Financial Advisors first reported a position in CYCN in Q1 2023 and held it in 2 quarters. The position peaked at $127K in Q1 2023. 17 funds tracked by Wall St. Rank hold CYCN as of Q3 2023.

  • CAPTRUST Financial Advisors reported no remaining Cyclerion Therapeutics position as of Q3 2023 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 14,631 Cyclerion Therapeutics shares in Q3 2023, an estimated $60.3K.
  • CAPTRUST Financial Advisors first reported a position in Cyclerion Therapeutics in Q1 2023 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Cyclerion Therapeutics position peaked at $127K in Q1 2023.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2023.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.